Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis
- PMID: 8364915
Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis
Abstract
Expression of two important glucose transporter proteins, GLUT 2 (which is the typical glucose transporter in hepatocytes of adult liver) and the erythroid/brain type glucose transporter GLUT 1 (representing the typical glucose transporter in fetal liver parenchyma), was studied immunocytochemically during hepatocarcinogenesis in rats at different time points between 7 and 65 wk after cessation of 7-wk administration of 12 mg/kg of body weight of N-nitrosomorpholine p.o. (stop model). Foci of altered hepatocytes excessively storing glycogen (GSF) and mixed cell foci (MCF) composed of both glycogenotic and glycogen-poor cells were present at all time points studied. Seven wk after withdrawal of the carcinogen, GSF were the predominant type of focus of altered hepatocytes. Morphometrical evaluation of the focal lesions revealed that the number and volume fraction of GSF increased steadily until Wk 65. MCF were rare at 7 wk, increased slightly in number and size until Wk 37, but showed a pronounced elevation in their number and volume fraction from Wk 37 to Wk 65. In both GSF and MCF, GLUT 2 was generally decreased or partially absent at all time points. Consequently, foci of decreased GLUT 2 expression showed a steady increase in number and volume fraction from Wk 7 to Wk 65. GLUT 1 was lacking in GSF but occurred in some MCF from Wk 50 onward. The liver type glucose transporter GLUT 2 was decreased in all adenomas and hepatocellular carcinomas (HCC). In three of seven adenomas and 10 of 12 carcinomas, expression of GLUT 1 was increased compared with normal liver parenchyma. In two cases of adenoid HCC, cells of ductular formations coexpressed GLUT 2 and GLUT 1. In contrast, normal bile ducts, bile duct proliferations, and cystic cholangiomas expressed only GLUT 1. Seven of 12 HCC contained many microvessels intensely stained for GLUT 1, a phenomenon never observed in normal liver. Whenever adenoid tumor formations occurred, GLUT 1-positive microvessels were located in the immediate vicinity of these formations. Only in one HCC were such microvessels found in the absence of adenoid formations. Our studies indicate that a reduction of GLUT 2 expression occurs already in early preneoplastic hepatic foci and is maintained throughout hepatocarcinogenesis, including benign and malignant neoplasms. Reexpression of GLUT 1, however, appears in a few MCF and in the majority of adenomas and carcinomas.
Similar articles
-
NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).Natl Toxicol Program Tech Rep Ser. 1996 Aug;383:1-370. Natl Toxicol Program Tech Rep Ser. 1996. PMID: 12692653
-
NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).Natl Toxicol Program Tech Rep Ser. 1993 Sep;422:1-340. Natl Toxicol Program Tech Rep Ser. 1993. PMID: 12616289
-
Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis.Am J Pathol. 1998 Feb;152(2):341-5. Am J Pathol. 1998. PMID: 9466558 Free PMC article.
-
[Sequential cellular and molecular changes during hepatocarcinogenesis].Verh Dtsch Ges Pathol. 1995;79:72-83. Verh Dtsch Ges Pathol. 1995. PMID: 8600697 Review. German.
-
Relevance of hepatic preneoplasia for human hepatocarcinogenesis.Toxicol Pathol. 2003 Jan-Feb;31(1):126-33. doi: 10.1080/01926230390173905. Toxicol Pathol. 2003. PMID: 12597457 Review.
Cited by
-
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.Oxid Med Cell Longev. 2018 Nov 4;2018:7512159. doi: 10.1155/2018/7512159. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30524660 Free PMC article. Review.
-
Glucose transporters as markers of diagnosis and prognosis in cancer diseases.Oncol Rev. 2022 Feb 22;16(1):561. doi: 10.4081/oncol.2022.561. eCollection 2022 Feb 22. Oncol Rev. 2022. PMID: 35340885 Free PMC article.
-
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.Am J Pathol. 2009 Apr;174(4):1544-52. doi: 10.2353/ajpath.2009.080596. Epub 2009 Mar 12. Am J Pathol. 2009. PMID: 19286567 Free PMC article.
-
Drugging cancer metabolism: Expectations vs. reality.Int Rev Cell Mol Biol. 2019;347:1-26. doi: 10.1016/bs.ircmb.2019.07.007. Epub 2019 Jul 29. Int Rev Cell Mol Biol. 2019. PMID: 31451211 Free PMC article. Review.
-
MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients.Braz J Med Biol Res. 2012 Jan;45(1):72-7. doi: 10.1590/s0100-879x2011007500160. Epub 2011 Dec 9. Braz J Med Biol Res. 2012. PMID: 22147193 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources